$SLS Gains 156% on a Phase 3 Leukemia Vaccine Win, Then Files a $150 Million Offering Overnight: The REGAL Fine Print, the Dilution Math, and the Zones From $10 to $35
SELLAS's cancer vaccine cut death risk 41% in Phase 3 AML (median survival 24.0 vs 14.7 months), sending the stock from $7.47 to $19.15 — then management filed a $150M offering after hours. The pro-forma cash math, the three things the headline glosses over, and the scenario zones from $10 to $35.
SELLAS Life Sciences ($SLS) spent Monday as a $1.5 billion biotech that most of the market had never priced for success. By Tuesday's close it was a $3.9 billion one. The company's cancer vaccine, galinpepimut-S, cut the risk of death by 41% in its pivotal Phase 3 REGAL trial in acute myeloid leukemia — median overall survival of 24.0 months against 14.7 months for best available treatment — and the stock went from a $7.47 Monday close to a $19.15 Tuesday close on 119.9 million shares traded, roughly ten times its recent volume and more than half its entire share count changing hands in a single session.
Then, after Tuesday's close, SELLAS did what every biotech with a fresh win and a thin balance sheet does: it filed to sell $150 million of stock, with J.P. Morgan and TD Cowen running the book.
That sequence — triple on the data, dilute overnight — is the whole setup. The cashtag stream is split between people who see a validated cancer vaccine with a hazard ratio of 0.59 and people who see a 126-patient open-label trial, a p-value of 0.035, and a management team hitting the sell button within hours of the print. Both camps are working with real facts. The question is what the distribution of outcomes actually looks like from $19.
What REGAL actually showed
The REGAL trial, per the topline results SELLAS filed with the SEC on Tuesday, enrolled 126 patients with acute myeloid leukemia who had achieved a second or later complete remission after salvage therapy and were ineligible for, or unable to undergo, an allogeneic stem cell transplant. That is a specific and brutal corner of the disease: patients who have already relapsed at least once, gotten back into remission, and have no transplant option. Historically, most of them relapse again, and quickly.
Patients were randomized 1:1 between galinpepimut-S (GPS) — a peptide immunotherapy targeting the WT1 antigen, originally developed at Memorial Sloan Kettering — as maintenance monotherapy, and investigator's choice of best available treatment: observation, hypomethylating agents, venetoclax, or low-dose cytarabine. The final analysis triggered at the 80th death, as pre-specified.
The topline numbers:
- Median overall survival: 24.0 months on GPS vs. 14.7 months on best available treatment — a 9.3-month gain in a population where survival is usually measured in months, not years.
- Hazard ratio: 0.59, a 41% reduction in the risk of death.
- Two-sided p-value: 0.035 — statistically significant against the 0.05 threshold.
- Safety: treatment-related adverse events were predominantly grade 1/2, mostly injection-site reactions, with no new safety signals. For a maintenance drug given to patients in remission, tolerability is not a side note — it is half the commercial argument.
The company says it plans to meet with the FDA to discuss an accelerated filing strategy and is targeting a Biologics License Application submission in the first half of 2027. Full secondary-endpoint analyses — leukemia-free survival, immune response data, measurable residual disease — are being saved for a medical conference and peer-reviewed publication.
If the data holds up, this would be among the first therapeutic cancer vaccines to demonstrate a significant overall survival benefit in a randomized Phase 3 trial in AML — a field littered with two decades of failures. That is why the stock gained 156% in a day — and briefly more than tripled intraday. It is also why the skeptics are circling: extraordinary results in a small open-label trial invite scrutiny, and the stock's fade from a $24.89 intraday high to a $19.15 close suggests plenty of holders chose to sell the headline rather than wait for the fine print.
The overnight dilution
The $150 million underwritten offering launched after Tuesday's close comes with a 30-day option for the underwriters to buy up to $22.5 million more. Pricing had not been announced as of Wednesday morning; the preliminary prospectus leaves the price blank. At Tuesday's $19.15 close, $150 million is roughly 7.8 million new shares against 203.9 million outstanding — call it 4% dilution, closer to 5% with the option exercised, and more if the deal prices at a meaningful discount, which these deals usually do.
By recent biotech standards that is a restrained raise — and that restraint, plus who is running it, tells you something. This is not a shelf dribbled out through an ATM; it is a marquee-bank underwritten deal sized to fund a BLA filing and commercial build-out. The balance sheet underneath it was already in decent shape, which makes the timing less desperate than it looks on the stream.
Where it gets interesting is what the combined entity looks like after the raise — and whether the trial's fine print supports the new $4 billion valuation. That is the part worth doing properly.
A free membership gets you access to every free article at AlphaBriefing.com: Join AlphaBriefing free.
The rest of this briefing is for paid members: the real share count and pro-forma cash math after the raise, the three things in the trial design that the headline number glosses over, the catalyst calendar from here to a 2027 BLA, and the scenario-by-scenario price zones from $10 to $35.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.